Clinical Trial Detail

NCT ID NCT03298984
Title Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Alvocidib + Cytarabine + Daunorubicin

Age Groups: adult senior

No variant requirements are available.